Why the study?
Long non-coding RNAs (lncRNAs) play important roles in cardiovascular disease progression, but novel lncRNAs, mRNAs, and key pathways involved in hypertrophic cardiomyopathy remained to be identified.
Population
Sequencing datasets GSE68316, GSE130036, and GSE89714 and plasma samples from patients with HCM
Design
Integrated bioinformatics co-expression network analysis with plasma sample validation
Authors
Loading...
Plasma lncRNAs may indicate HCM biomarkers; animal data leaves open validation and therapeutic translation.
Integrative network analysis identified three pivotal lncRNAs (LA16c-312E8.2, RP5-1160K1.3, and MIR22HG) that may serve as novel biomarkers and therapeutic targets for hypertrophic cardiomyopathy.
Cao et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: